__NUXT_JSONP__("/drugs/Tucatinib", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:a,conditionIndication:"Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑HER2 treatment regimens.",inn:"tucatinib",marketingAuthorisationDate:"2021-02-11 01:00:00",marketingAuthorisationHolder:"Seagen B.V.",medicineName:b,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Ftukysa"}],fdaDrugLabel:[{brand:"TUKYSA",indication:"1 INDICATIONS AND USAGE TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. ( 1 )",manufacturer:"SEAGEN INC.",splSetId:"f27eb1b9-b7fc-424e-988f-84dd7bb195a3"}],id:a,nciThesaurus:{casRegistry:"937263-43-9",chebiId:c,chemicalFormula:c,definition:"An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.",fdaUniiCode:"234248D0HH",identifier:"C77896",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C159156"],synonyms:["ARRY-380","Irbinitinib","N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine","ONT-380","TUCATINIB",a,b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FTucatinib",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Tucatinib","Tukysa","","2021-10-30T13:44:58.813Z")));